{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-006081","form_type":"8-K","ticker":"BIXT","cik":"0001445815","company_name":"BIOXYTRAN, INC","filed_at":"2026-02-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.100608+00:00","generated_at":"2026-05-16T03:16:29.150961+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Bioxytran reports Phase 2 ProLectin-M shows 100% viral clearance at day 7; p=0.001","bullets":["100% of treated subjects achieved complete viral clearance by Day 7 vs placebo (p=.001).","No viral rebounds observed during the 14-day post-treatment observation period.","16 of 38 subjects had non-detection by Day 5; 1 of 38 by Day 3.","Phase 2 dose-optimization trial: randomized, double-blind, 38 subjects completed.","Company plans regulatory discussions for late-stage development and additional viral indications."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-006081","json":"https://secwatch.observer/filing/0001493152-26-006081.json","markdown":"https://secwatch.observer/filing/0001493152-26-006081.md","text":"https://secwatch.observer/filing/0001493152-26-006081.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1445815/000149315226006081/0001493152-26-006081-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1445815/000149315226006081/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T03:16:29.150961+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}